Trial Information
A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer
Inclusion Criteria:
- Patients with adenocarcinoma of the prostate
- Subjects with locally advanced, and/or metastatic prostate cancer for whom surgical
castration or other medical interventions are not considered appropriate or
acceptable
Exclusion Criteria:
- Any known history of abnormal liver function tests
- Any severe concomitant condition that would make it undesirable, in the clinician's
opinion, for the subject to participate in the trial.
- Known hypersensitivity to bicalutamide or any of the components found in bicalutamide
Type of Study:
Expanded Access
Study Design:
N/A
Authority:
United States: Food and Drug Administration
Study ID:
7054US/0014
NCT ID:
NCT00636259
Start Date:
Completion Date:
Related Keywords:
- Adenocarcinoma of the Prostate
- Prostate cancer
- Casodex
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Prostatic Neoplasms